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Abstract Excessive accumulation of lipofuscin in postmitotic
retinal pigment epithelial cells is a common pathogenetic path-
way in various blinding retinal diseases including age-related
macular degeneration, which is now the most common cause
of registerable blindness in the industrialized nations. To better
understand the role of lipofuscin accumulation and to manipu-
late the pathogenetic mechanisms on both experimental and
therapeutic levels we analyzed the proteome of isolated human
ocular lipofuscin granules from human RPE cells. After homog-
enization and fractionation by gradient ultracentrifugation of
the RPE/choroid complex from 10 pairs of human donors, pro-
tein compounds were separated by 2D gel electrophoresis and
analyzed using matrix-assisted laser desorption/ionization mass
spectrometry and HPLC-coupled electrospray tandem mass
spectrometry. Besides a better understanding of downstream
pathways, this approach may provide new targets for therapeu-
tic interventions in a currently untreatable disease. ) 2002
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1. Introduction
Accumulation of lipofuscin is a common phenomenon in
ageing cells [1]. In postmitotic retinal pigment epithelial
(RPE) cells, lipofuscin accumulates with age and in associa-
tion with various blinding retinal diseases including degener-
ative and hereditary entities [2,3]. Normal RPE cell function is
an essential prerequisite for photoreceptor and, thus, neuro-
sensory retinal function [4]. Lipofuscin composition is thought
to vary to a large extent in di¡erent tissues including neuronal
cells of the central nervous system or hepatocytes [1]. In hu-
man RPE cells, several lines of evidence indicate that lipofus-
cin is a potentially deleterious byproduct of the constant
phagocytosis of shed distal photoreceptor outer segment
(ROS) disks [5]. Normally, degradation of this phagocytic
load throughout life occurs in the lysosomal compartment
with subsequent release of degraded material at the basal
cell side and clearance by the choriocapillaris [5]. The mech-
anisms of lipofuscinogenesis are currently incompletely under-
stood. The occurrence in a variety of monogenetic retinal
diseases such as Stargardt’s disease (mutations in the ABCR
gene) and Best’s disease (mutations in the VMD2 gene) sug-
gests that excessive accumulation of lipofuscin represents a
common downstream pathogenetic pathway of various molec-
ular etiologies [6,7]. There is both experimental and clinical
evidence that lipofuscin in this particular cell phenotype is
associated with cellular dysfunction and subsequent impair-
ment of visual function in corresponding retinal areas [8,9].
In humans, photoreceptor density was found to correlate with
the lipofuscin concentration of the apposing RPE cells [10]. In
vivo investigations using confocal scanning laser ophthalmos-
copy have demonstrated excessive lipofuscin accumulation in
association with various manifestations of age-related macular
degeneration (AMD) [11]. The development of atrophy has
been found to occur in areas of increased lipofuscin-mediated
fundus auto£uorescence in a longitudinal study in patients
with AMD [11]. Direct evidence that an individual component
of lipofuscin interferes with metabolic functions of RPE cells
has not been demonstrated until recently [12].
Electron microscopic studies have shown a stepwise conver-
sion of lysosomal structures to lipofuscin granula. Although
lysosomal hydrolytic enzymes are capable of degrading most
cellular macromolecules, it is assumed that lipofuscin results
from an incomplete degradation in secondary lysosomes and/
or the presence of altered biomolecules that are not degrad-
able [13]. Lipid oxidation has been suggested to play a role
[14], whereby the pigments may arise as a consequence of
antioxidant de¢ciency or under prooxidant conditions [15,
16]. Once formed, the RPE cell has no means of degrading
or transporting lipofuscin material and granules into the extra-
cellular space via exocytosis. Subsequently, these granules are
trapped in the cytoplasm. An age-dependent accumulation of
RPE lipofuscin has been described applying various in vitro
and in vivo methods [8,17].
Only few compounds of RPE lipofuscin have been identi-
¢ed to date [18]. Current knowledge suggests that lipofuscin is
a heterogenous mixture of various biomolecules partially
modi¢ed by oxidation and lipidperoxidation due to excessive
UV-irradiation and high oxygen levels in the eye [19]. More
than 10 di¡erent £uorophores have been identi¢ed [18]. A2-E
(N-retinylidene-N-retinylethanolamine), a major retinoid com-
ponent of RPE lipofuscin, which represents a Schi¡ base
product of all-trans retinaldehyde and ethanolamine (ratio
2:1) has recently been shown to cause a striking inhibition
of major lysosomal catabolic pathways in cultured human
RPE cells in concentrations that occur in vivo [12,20,21].
While interference with normal cell function has been eluci-
dated for A2-E, we speculate that lipofuscin granules may
contain other potentially toxic compounds. Furthermore, an
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expanded analysis of lipofuscin components may give insights
into pathogenetic mechanisms and may, thus, provide new
targets for designing e¡ective therapeutic strategies in this
currently untreatable blinding retinal disease. Therefore, we
sought to determine the proteinous composition of isolated
human ocular lipofuscin by applying modern protein analyt-
ical methods. To our knowledge this study represents the ¢rst
description of the human lipofuscin proteome.
2. Materials and methods
2.1. Lipofuscin isolation
Lipofuscin was isolated using a procedure of Boulton et al. [22].
Brie£y, the RPE/choroid complex of 10 pairs of eyes derived from
donors of corneal transplantations with no known ophthalmologic
disease aged between 61 and 97 years were collected and stored at
320‡C. Post mortem times varied between 24 and 48 h. The cells of
the complex were homogenized on ice in a Potter-Elvejem-Homoge-
nizator using phosphate-bu¡ered saline (PBSA) and centrifuged at
60Ug for 7 min. to remove cellular debris. Then pigment granules
were pelleted by centrifugation (6000Ug/10 min.), resuspended in 4 ml
0.3 M sucrose, and layered on a discontinuous gradient built of eight
di¡erent concentrations of sucrose: 2.0, 1.8, 1.6, 1.55, 1.5, 1.4, 1.2 and
1.0 M (4 ml each). Identi¢cation of pure lipofuscin in the ¢rst band
was done by analysis of excitation and emission spectra of isolated
lipofuscin as described by Boulton et al. [23] using the high perfor-
mance spectral£uorometer SFM 25 (Kontron). The ¢rst orange-
brown band between 1.0 and 1.2 M sucrose containing pure Lipofus-
cin was collected using a Pasteur pipet. Lipofuscin was resuspended in
0.3 M sucrose and puri¢ed on a second sucrose gradient. Dilution in
PBSA, centrifugation at 6000Ug for 10 min. and washing three times
in PBSA followed. The samples were stored at 320‡C.
2.2. Protein content of lipofuscin
Lipofuscin-related proteins were extracted from isolated lipofuscin
with 0.5 M NaOH. Protein concentration was measured using the
method of Lowry et al. applying bovine serum albumin as standard
[24].
2.3. 2D gel electrophoresis of lipofuscin
Isoelectric focusing (IEF) was performed using dry polyacrylamide
gel strips (IPG, 11 cm) with an immobilized pH gradient pH 3^10 and
the IPGphor1 Isolectric Focusing System (Amersham Pharmacia
Biotech). IPG strips were rehydrated in reswelling bu¡er [7 M urea,
2 M thiourea, 4% Triton X-100, 65 mM dithiothreitol (DTT), 0,8%
Pharmalite] overnight. Lipofuscin protein was extracted in reswelling
bu¡er and 80 Wl were pipetted into the sample cup of each strip
holder. The IEF protocol started at 100 V for 16 h followed by
500 V for 1 h, 500^8000 V (linear increase) within 10 h and ¢nally
8000 V for 4.5 h.
The Multiphor II £atbed system and ExcelGel1, gradient 8^18 was
used for sodium dodecylsulfate^ polyacrylamide gel electrophoresis
(SDS^PAGE) as second dimension. Equilibration bu¡er for IPG
strips contained 50 mM Tris^HCl, pH8.5, 2% SDS, 6 M urea, 30%
glycerol and 65 mM DTT for the ¢rst 15 min. followed by 260 mM
iodoacetamide. After draining the equilibration solution on ¢lter pa-
per the IPG strips and prestained SDS^PAGE standards (Bio-Rad)
were placed on the SDS gel. Electrical settings were 600 V, 20 mA,
30 W for 50 min, followed by increase of current up to 50 mA. The
gel was ¢nally stained with colloidal Coomassie G50 (Perbio) for
5 days [25].
2.4. Tryptic digestion
Protein spots were excised from the gel and washed twice with
deionized water, 50% acetonitrile/water 1:1 and acetonitrile. Proteins
were digested with 33^165 ng sequencing grade modi¢ed trypsin
(Promega) in 40 mM ammonium bicarbonate at 37‡C overnight.
The reaction was stopped by freezing [25].
2.5. Matrix-assisted laser desorption ionization (MALDI) mass
spectrometry
MALDI mass spectra were recorded in the positive ion re£ector
mode with delayed extraction on a Re£ex II time-of-£ight instrument
(Bruker-Daltonik GmbH, Bremen, Germany) equipped with a
SCOUT multiprobe inlet and a 337 nm nitrogen laser. Ion accelera-
tion voltage was set to 26.5 kV, the re£ector voltage was set to 30.0
kV and the ¢rst extraction plate was set 20.6 kV [25]. Mass spectra
were obtained by averaging 200^300 individual laser shots. Calibra-
tion of the spectra was performed internally by a two-point linear ¢t
using autolysis products of trypsin. Sample preparation for MALDI
mass ¢ngerprints was achieved by cocrystallization of matrix (K-cya-
no-4-hydroxy cinnamic acid) with ZipTip C18 (Millipore, Bedford,
MA, USA) concentrated samples. Database search was done against
the NCBInr database using the MASCOT search algorithm
(www.matrixscience.com).
2.6. On-line high-performance liquid chromatography (HPLC)-coupled
ESI MS/MS
LC separations of the tryptic digests were performed using a Ulti-
Mate Capillary/Nano-HPLC system (Dionex, Sunnyvale, CA, USA).
After preconcentration using a 0.3 mmU1 mm C18 Pepmap column
(LC-Packings, San Francisco, CA, USA), the peptide mixture was
separated on a 75 Wm IDU250 mm C18 Pepmap column (LC-Pack-
ings) with a £ow rate of 190 nl/min and a linear gradient from 8 to
46% acetonitrile in 0.1% aqueous TFA in 55 min. The HPLC system
eluent was connected to a Finnigan MAT LCQ ion trap mass spec-
trometer (ThermoFinnigan, San Jose, CA, USA) equipped with a
nanospray source (Protana, Odense, Denmark). Spray voltage was
set to 1.5 kV and heated capillary temperature was 200‡C. After
performing one scan in MS mode from 300 to 2000 Da, the three
most intense ions in the scan were selected and subjected to CID.
Database search was done using TurboSequest 2.0 (ThermoFinnigan,
San Jose, CA, USA).
3. Results
Spectral characteristics of isolated lipofuscin corresponded
to previously published spectra of pure RPE lipofuscin (Fig. 1)
and light microscopic examination [22,23] of the puri¢ed gran-
ules con¢rmed their purity (data not shown). Extraction of
lipofuscin isolated from 10 eyes yielded 18.9 mg of protein.
2D gel electrophoresis of extracted proteins resulted in the
separation of 81 individual protein spots (Fig. 2). The spots
were excised from the gel, digested with trypsin and analyzed
by MALDI mass spectrometry. Proteins were subsequently
identi¢ed by data base search with the obtained peptide
mass ¢ngerprints (Table 1). In addition, most of the samples
Fig. 1. Excitation and emission spectra of human ocular lipofuscin
were recorded on a Kontron SFM 25 £uorimeter. The excitation
spectrum was recorded at a constant emission wavelength of 430
nm. For recording of the emission spectrum, excitation was set at
360 nm. Spectra were corrected by subtracting measurements of
pure solvent.
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were also analyzed by HPLC-coupled ESI MS/MS to con¢rm
the MALDI results by sequence data. Most of the identi¢ed
proteins represent abundant cellular proteins, including cyto-
skeleton proteins, proteins of phototransduction, enzymes of
metabolism, proteins of the mitochondrial respiratory chain,
ion channel proteins and chaperones, which are known to
occur in photoreceptors, RPE and other cell types. Remark-
able is the occurrence of recoverin (spot 58), since it represents
a photoreceptor cell-speci¢c protein [26]. Four spots could not
be identi¢ed due to missing database hits. Clusters of spots
containing the same protein, e.g. spots 12^14, 34^36, 37^39,
47^49, 52^53, 55^56 and 63^65 may represent di¡erent post-
translationally modi¢ed forms. For most of the spots the ex-
perimental molecular weight corresponded closely to the the-
oretical mass as deduced from the database. Only a few spots
(20, 29, 31, 54, 57) indicated a lower molecular weight as
compared to theoretical data, and one spot (49) exhibited a
signi¢cantly higher experimental mass. Five spots were iden-
ti¢ed as hemoglobin chains probably representing blood con-
taminations during lipofuscin preparation.
4. Discussion
This is, to our knowledge, the ¢rst description of the pro-
tein components of human ocular lipofuscin isolated from
RPE cells. Lipofuscin in postmitotic RPE cells is thought to
be mainly a byproduct of the constant phagocytosis and deg-
radation of shedded ROS. Therefore, lipofuscin should con-
tain degradation products of photoreceptor-derived proteins.
Indeed most of the identi¢ed protein components of lipofuscin
have been shown to occur in photoreceptors, but many are
also abundant in various other cell types, including RPE. The
presence of the ROS-speci¢c protein recoverin [26] under-
scores the contribution of phagocytosed ROS to lipofuscin.
On the other hand, various mitochondria-derived proteins
(e.g. in spots 18, 20, 23, 24, 27, 33, 40, 57, 60, 67, 75) were
detected in lipofuscin granules, although ultrastructural ex-
aminations indicate that mitochondria are concentrated in
photoreceptor inner segments, whereas ROS lack these organ-
elles [27]. Thus a considerable proportion of lipofuscin is
likely to originate from autophagic processes in the RPE
cell itself.
The cytoplasmic space of aged RPE cells or cells with early
excessive lipofuscin accumulation may be occupied by lipofus-
cin granules to large extend. It has been suggested that these
vast intracellular deposits in membranous bags may physically
impair cellular structure and function [28]. While it has ini-
tially been assumed that lipofuscin is merely an inert mixture
of various biomolecules, several lines of evidence now indicate
that it contains various cytotoxic compounds. Since the ma-
jority of the proteins identi¢ed herein are cellular house keep-
ing proteins which per se would not be expected to have toxic
properties, posttranslational modi¢cations may result in gen-
eration of toxic substances. In particular, UV light in associ-
ation with high oxygen concentrations causing permanent per-
oxidation of polyunsaturated lipids in the membrane system
of photoreceptors ¢nally may result in the generation of mal-
ondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) which
are known to modify proteins and initiate crosslinking. Such
modi¢cation may hinder protein degradation by the lysosomal
system, thereby contributing to lipofuscin deposition [13].
Furthermore, deposition of MDA- and 4-HNE-protein-
adducts might be actively involved in the pathogenesis of
AMD by inducing an in£ammatory process [29]. Therefore,
such posttranslational modi¢cations of lipofuscin-associated
proteins are currently investigated in our laboratory.
For most of the proteins identi¢ed, the molecular weight
deduced from the position of the spots corresponded to the
expected molecular weight. Therefore, intermolecular cross-
linking of proteins to form higher complexes is unlikely. For
some proteins (spots 20, 29, 31, 54, 57) the position in the gel
was shifted to a lower molecular weight, probably indicating
the accumulation of proteolytic degradation products in lipo-
fuscin.
Opsin, the major protein component of ROS, was not de-
tected in lipofuscin, suggesting that a high concentration of a
protein in the phagocytosed material does not necessarily lead
to its accumulation in lipofuscin granules.
The observation that human ocular lipofuscin contains sev-
eral subunits of ATPase (spots 18, 23, 24, 57), interestingly,
shows parallels to Batten disease (juvenile ceroid-lipofuscino-
sis), an inherited disorder which is characterized by massive
lysosomal accumulations of subunit c of the mitochondrial
ATP synthase complex. The disease results in total blindness
due to retinal degeneration [30]. In an experimental model of
the disease, accumulation of subunit c-containing auto£uor-
escent lysosomal storage bodies is linked to severe retinal and
neurologic degenerations [31].
Lipids, in particular carotenoids and retinoids, are also
characteristic components of RPE lipofuscin and have been
implicated in the pathogenesis of AMD. At present, the con-
tribution of single compounds of lipofuscin to disease process-
es cannot yet be veri¢ed. A concerted action of various li-
pofuscin constituents appears likely. Our present study
provides a starting point for further investigations on the
potential role of the proteinous component of lipofuscin in
the pathobiochemistry of various blinding retinal diseases in-
cluding AMD.
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Fig. 2. Separation of lipofuscin proteins by 2D gel electrophoresis
in an immobilized pH gradient from 3 to 10 with subsequent colloi-
dal Coomassie staining as described in Section 2. Stained spots were
identi¢ed by MALDI and ESI mass spectrometry and listed in Ta-
ble 1 with corresponding numbers. Molecular weight markers (kDa)
are shown at the left margin.
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Table 1
Proteome analysis of lipofuscin in human retinal RPE cells
Spot Protein NCBI MW (kDa)
1 Hypothetical protein (alpha-spectrin homolog) 7512790 152.4
2 Not identi¢ed
3 Tumor rejection antigen (gp96) 4507677 92.7
4 Tumor rejection antigen (gp96) 4507677 92.7
5 Not identi¢ed
6 Hexokinase 1 15991833 102.2
7 Not identi¢ed
8 Motor protein 5803115 84.0
9 Valosin-containing protein 6005942 90.0
10 Heat shock protein HSP 90-alpha (HSP 86) 123678 85.0
11 Heat shock 70 kDa protein 5 16507237 72.3
12 Annexin VI (Lipocortin VI) 113962 75.8
13 Annexin VI (Lipocortin VI) 113962 75.8
14 Annexin VI (Lipocortin VI) 113962 75.8
14a Heat shock 70 kDa protein 8 5729877 70.8
15 Calreticulin precursor; Sicca syndrome antigen A 4757900 48.1
16 Tubulin, beta chain 5174739 49.6
Prolyl-4-hydroxylase beta-subunit 2507460 57.0
17 Tubulin, alpha-1 chain 135395 50.8
17a Tubulin beta chain 135448 50.2
18 ATP synthase beta chain 1145449 56.5
19 Enolase 2, gamma 5803011 47.6
20 Ubiquinol-cytochrome c reductase core protein I 4507841 53.3
21 Pyruvate kinase, muscle 14750405 58.5
22 Pyruvate kinase, muscle 14750405 58.5
23 ATP synthase, alpha subunit 4757810 59.7
24 ATP synthase, alpha subunit 4757810 59.7
25 Enolase 1, alpha 4503571 47.5
26 Enolase 1, alpha 4503571 47.5
27 S-arrestin 14737493 45.3
NADH dehydrogenase Fe-S protein 2 4758786 52.5
28 Glutamate-ammonia ligase 15297214 42.7
Tu translation elongation factor 4507733 49.5
NADH dehydrogenase Fe-S protein 2 4758786 52.5
29 Serum albumin 28592 71.3
30 Creatin kinase 180570 42.9
30a Beta actin 4501885 42.1
31 Vimentin 14742600 53.7
32 Guanine nucleotide-binding protein (0), alpha subunit 2 232134 40.6
33 Guanine nucleotide-binding protein, beta polypeptide 2 4885283 38.1
Pyruvate dehydrogenase 2144337 39.2
34 Annexin A2 16306978 38.8
35 Annexin A2 16306978 38.8
36 Annexin A2 16306978 38.8
37 Glyceraldehyde-3-phosphate dehydrogenase 31645 36.2
38 Glyceraldehyde-3-phosphate dehydrogenase 31645 36.2
39 Glyceraldehyde-3-phosphate dehydrogenase 31645 36.2
40 Ubiquinol-cytochrome c reductase core protein II 14775827 48.6
41 Porin 31HM (anion channel 1) 238427 30.7
42 Voltage-dependent anion channel 2 4507881 32.1
43 Porin 31HM (anion channel 1) 238427 30.7
44 Not identi¢ed
45 Voltage-dependent anion channel 2 4507881 32.1
46 Glyceraldehyde-3-phosphate dehydrogenase 31645 36.2
47 H119n carbonic anhydrase Ii 2554664 29.1
48 H119n carbonic anhydrase Ii 2554664 29.1
48a Phosphoglycerate mutase 1 4505753 28.9
49 Crystallin, beta B2 4503063 23.5
50 Annexin IV 14738103 27.2
51 Annexin V (Lipocortin V) 999937 35.8
Retinaldehyde binding protein 1 4506541 36.5
52 Tyrosine 3-monooxygenase/tryptophan 5-monoox. activation protein, epsilon 5803225 29.3
53 Tyrosine 3-monooxygenase/tryptophan 5-monoox. activation protein, theta 5803225 29.3
Tyrosine 3-monooxygenase/tryptophan 5-monoox. activation protein, beta 4507949 28.1
Tyrosine 3-monooxygenase/tryptophan 5-monoox. activation protein, zeta 4507953 27.7
54 Cathepsin D 4503143 45.0
55 Prohibitin 4505773 29.8
56 Prohibitin 4505773 29.8
56a Cathepsin D 4503143 45.0
57 ATP synthase, subunit d 5453559 18.5
58 Recoverin 4506459 23.2
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Table 1 (Continued).
Spot Protein NCBI MW (kDa)
59 Calmodulin 2 (phosphorylase kinase, delta) 14250065 16.8
60 ATP synthase, H+transporting 4502297 17.4
61 Cytochrome c oxidase subunit Va precursor 4758038 16.9
62 Peroxiredoxin 2 13631440 22.0
63 Crystallin, alpha A 4503055 20.0
64 Crystallin, alpha B 4503057 20.1
65 Crystallin, alpha B 4503057 20.1
66 Neuropolypetide h3 9131159 21.0
67 Ubiquinol-cytochrome c reductase bindidng protein 5454152 13.5
Hemoglobin alpha 2 4504345 15.3
68 Delta globin 4504351 16.2
69 Hemoglobin alpha 1 globin chain 13195586 10.7
70 Chain A, P11 (S100a10), ligand of annexin Ii 3212355 11.2
71 Mutant hemoglobin beta chain 18418633 16.1
72 Mutant hemoglobin beta chain 18418633 16.1
73 Mutant hemoglobin beta chain 18418633 16.1
74 Cellular retinoic acid binding protein 1 18314500 15.7
75 Cytochrome c oxidase subunit Vib 4502985 10.4
76 Glial ¢brillary acidic protein 17479453 42.2
FEBS 26521 11-9-02
F. Schutt et al./FEBS Letters 528 (2002) 217^221 221
